Skip to main content

Table 2 Treatment-related adverse events reported in ≥ 10% of patients (n = 27)

From: Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Drug-related AE

All grades

N (%)

Grade 3

N (%)

Fatigue

13 (48%)

4 (15%)

Rash

12 (44%)

7 (26%)

Vomiting

8 (30%)

0

Nausea

7 (26%)

0

Diarrhea

7 (16%)

0

Pain

5 (19%)

1 (4%)

AST increased

4 (15%)

2 (7%)

Hyperglycemia

4 (15%)

1 (4%)

Pruritus

4 (15%)

1 (4%)

Anorexia

4 (15%)

0

Mucositis

4 (15%)

0

Insomnia

3 (11%)

0

Anemia

3 (11%)

0

Sore throat

3 (11%)

0

Dysgeusia

3 (11%)

0

Constipation

3 (11%)

0